QNTM DEADLINE: Investors of Quantum Biopharma Ltd. (QNTM) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 23, 2026

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"QNTM DEADLINE: Investors of Quantum Biopharma Ltd. (QNTM) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 23, 2026NEW YORK, NY - January 7, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).\nCLICK HERE TO JOIN THE CASE\nIf you sold Quantum securities during the Class Period and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or [email protected], or by calling (800) 290-1952.\n\nDEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than February 23, 2026, to serve as a lead plaintiff for the purported class.  If you have losses, we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.\nThe complaint alleges that “spoofing” is a manipulative and illegal trading practice that involves submitting and then cancelling buy or sell orders without any genuine intent to execute them. \nThe complaint alleges that during the Class Period, Defendants repeatedly entered thousands of spoofed sell orders designed to create the false impression in the market that Quantum’s stock price was falling and that these manipulative orders were calculated to (and successfully did) deceive or induce other investors to sell their holdings at artificially low prices. Further, the complaint alleges that Defendant’s purchased shares at these artificially depressed levels and positioned themselves to profit at the same time that investors were baited into selling shares at artificially depressed prices.\nWHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chi...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B